Realcan Pharmaceutical Group Co Ltd

Realcan Pharmaceutical Group Co Ltd has a debt-to-equity ratio of 0.9, indicating a moderate level of leverage. The company's liquidity is assessed as medium, with a current ratio of 1.09, suggesting it has just enough current assets to cover its current liabilities. The company's free cash flow is minimal at 964,190 CNY, and its operating cash flow is only 13,759,530 CNY, which may limit its ability to fund operations and growth without external financing.

In terms of profitability, the company's return on equity is 0.3%, and its return on assets is 0.11%, both of which are below the typical thresholds for strong performance in the pharmaceutical industry. These figures suggest that the company is not generating significant returns relative to its equity and asset base. The gross profit of 776,057,360 CNY and operating income of 16,516,400 CNY indicate that the company is generating some profit, but the margins are thin.

The company's revenue is concentrated in a single business segment, as no segment breakdown is provided in the available data. Geographically, the company's exposure is not specified, but the lack of segment data suggests that it may not have significant international operations. The company's capital expenditure is negative at -26,820,910 CNY, indicating that it is not investing in new assets and may be reducing its capital base.

The company's growth trajectory is not clearly defined, as no specific revenue growth rates or future projections are provided. The analyst estimate for the last actual revenue is 27,203,883,920 CNY, which is higher than the reported revenue of 7,295,858,460 CNY, suggesting a potential discrepancy or a need for further clarification. The company's net income of 16,071,180 CNY is relatively low, which may indicate challenges in maintaining profitability.

The company's risk assessment indicates a medium liquidity risk and a low dilution risk. The key flag of negative net cash after subtracting total debt suggests that the company may face liquidity constraints in the near term. The company's capital structure, with a high level of long-term debt, may also pose a risk if interest rates rise or if the company's cash flow is insufficient to service its debt obligations.

Recent events and filings do not provide specific details about the company's operations or strategic initiatives. The lack of detailed information may indicate that the company is not actively disclosing new developments or that the available data is limited. The company's financial performance and risk profile suggest that it may need to focus on improving its profitability and liquidity to support sustainable growth.

Realcan Pharmaceutical Group Co Ltd (002589.SZ) has been formally classified within the Healthcare economic sector, with its primary activity identified as Pharmaceuticals & Medical Research. This taxonomic update provides a clearer structural definition of the company’s operational focus, aligning its profile with industry standards for firms engaged in drug development and medical research. Alongside this classification, the company’s risk assessment framework has been initialized with specific metrics. Dilution risk is currently assessed as low, suggesting that existing shareholders face minimal immediate threat from equity expansion. This stability in capital structure is a positive indicator for long-term value preservation. Conversely, liquidity risk has been flagged as medium. This assessment highlights potential constraints in the ease of trading or converting assets, which investors should monitor as a key factor in short-term market dynamics. The contrast between low dilution risk and medium liquidity risk offers a nuanced view of the company’s financial health. These updates represent the first tracked-field changes for Realcan Pharmaceutical Group, establishing a baseline for future analysis. With no current analyst coverage or index membership recorded, these foundational classifications and risk assessments serve as the primary reference points for understanding the company’s market position and financial characteristics.